Cited by 43Liver Disease Diagnosis and TreatmentLiver Diseases and ImmunityLiver Disease and Transplantation

Liver‐related and extrahepatic events in patients with non‐alcoholic fatty liver disease: a retrospective competing risks analysis

Open access
Pennisi, Grazia, Enea, Marco, Romero‐Gomez, Manuel, Viganò, Mauro, Bugianesi, Elisabetta, Wong, Vincent W.‐S., Fracanzani, Anna Ludovica, Sebastiani, Giada +12 more·2022·Alimentary Pharmacology & Therapeutics

Abstract

Summary: Background & Aim: Non‐alcoholic fatty liver disease (NAFLD), and especially fibrotic non‐alcoholic steatohepatitis, is associated with high risks of liver‐related events (LRE) and extrahepatic events (EHE). We evaluated the competitive risk occurrence of LRE and EHE in a large cohort of biopsy‐proven NAFLD stratified according to baseline severity of fibrosis. Methods: Two thousand one hundred thirty‐five patients with biopsy‐proven NAFLD were enrolled. Observed cumulative incidence functions (CIFs) were used to evaluate the risk of LRE and EHE; cause‐specific Cox model and predicted CIFs were fitted to identify predictors of LRE and EHE. A replication cohort of NAFLD patients with liver fibrosis severity estimated by liver stiffness measurement by transient elastography was also enrolled. Results: Observed CIFs indicated that the 60‐month probabilities of LRE and EHE were 0.2% and 3% in F0‐F1, 2% and 3.8% in F2 and 9.7% and 6.4% in F3‐F4 patients, respectively. The cause‐specific Cox model indicated that in F0‐F1 and F2 patients, age > 50 years (HR 2.7) was the only predictor of LRE, while age > 50 years (HR 2.96), previous cardiovascular events (CVE, HR 2.07), and previous extra‐hepatic cancer (HR 2.36) were independent risk factors for EHE. In F3‐F4 patients, age > 55 years (HR 1.73), obesity (HR 1.52), PLT < 150 000/mmc (HR 3.66) and log(GGT) (HR 1.77) were associated with LRE, while age > 55 years (HR 1.74) and previous CVE (HR 2.51) were independent predictors of EHE. Predicted CIFs for HE and EHE in F0‐F1, F2 and F3‐F4 patients stratified the risk of events. The results were externally replicated. Conclusion: The likelihood of EHE in NAFLD patients is relevant and increases according to the severity of liver fibrosis, while the risk of LRE is negligible in F0‐F1, low but clinically relevant in F2 and high in F3‐F4 patients.

Integrity signals

Registry

Crossref · 10.1111/apt.16763

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Most patients with non-advanced NAFLD (fibrosis stage 0-2) primarily show extrahepatic events during follow-up, and the predominant cause of death in these patients is cardiovascular disease rather than liver-related events.

    “most patients with non‐advanced NAFLD (i.e. Fibrosis Stage 0–2) primarily show extrahepatic events during follow‐up and the predominant cause of death in these patients derives from cardiovascular disease rather than from liver‐related events [7, 8].”

    From Current treatment of non‐alcoholic fatty liver disease (2022) · cites this paper as [8]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Pennisi, G., Enea, M., Romero‐Gomez, M., Viganò, M., Bugianesi, E., Wong, V. W. ‐., Fracanzani, A. L., Sebastiani, G., Boursier, J., Berzigotti, A., Eslam, M., Ampuero, J., Benmassaoud, A., La Mantia, C., Mendoza, Y. P., George, J., Craxì, A., Camma', C., de Ledinghen, V., & Petta, S.
Affiliations
  • Palermo Italy
  • Seville Spain
  • Milan Italy
  • Turin Italy
  • Hong Kong China
  • Montreal Quebec Canada
  • Angers France
  • Bern Switzerland
  • Sydney New South Wales Australia
  • Pessac France
Corresponding author
Petta, Salvatore
Venue
Alimentary Pharmacology & Therapeutics
Publisher
Wiley
Published
2022-01-05
Volume
55
Issue
5
Pages
604-615
ISSN
  • 0269-2813 (ISSN-L)
  • 1365-2036
OpenAlex
W4206151377
Cited by
43
References
8
Citations by year
2026: 4 · 2025: 9 · 2024: 11 · 2023: 11 · 2022: 8
FWCI
7.04
Type
journal article
Language
en
Open access
Locations
  • Alimentary Pharmacology & Therapeutics (publishedVersion)
  • PubMed (publishedVersion)
  • Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
  • HAL (submittedVersion)
  • BORIS (University Library Bern) (submittedVersion)
  • Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion)
Topics
  • Health Sciences › Medicine › Epidemiology › Liver Disease Diagnosis and Treatment
  • Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
  • Health Sciences › Medicine › Hepatology › Liver Disease and Transplantation
Keywords
non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, liver-related events, liver fibrosis severity, competing risks, cardiovascular events, extrahepatic cancer, liver stiffness measurement, transient elastography, risk factors, platelet count, gamma-glutamyl transferase, obesity, age, cumulative incidence function
MeSH terms
Biopsy, Fibrosis, Humans, Liver, Liver Cirrhosis, Middle Aged, Retrospective Studies, Elasticity Imaging Techniques, Non-alcoholic Fatty Liver Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review